Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bola Adamolekun

Neurology Arlington, TN Medical Doctor

NPI 1104816990 CMS profile 321807

12085 Brooks River Drive, Arlington, TN 38002

Open in the dashboard

General payments

$20,261

216 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$85,209 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Bola Adamolekun of Arlington, TN is reported in the CMS Open Payments database as having received $20,261 across 216 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $85,209 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $835 2
2024 General $2,265 8
2023 General $54 3
2022 General $1,382 6
2021 General $3,179 81
2020 General $7,492 49
2019 General $5,053 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bola Adamolekun
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Bola Adamolekun were reported at $835. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Bola Adamolekun Neurology median Middle half National median
2019 $5,053 $474 $118–$2,177 $163
2020 $7,492 $367 $82–$2,309 $114
2021 $3,179 $438 $104–$2,547 $132
2022 $1,382 $442 $103–$2,388 $149
2023 $54 $464 $119–$2,312 $160
2024 $2,265 $468 $119–$2,323 $164
2025 $835 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $5,759 15 payments
  2. Allergan Inc. $5,288 27 payments
  3. Merck Sharp & Dohme Corporation $3,450 5 payments
  4. SK Life Science, Inc. $2,243 22 payments
  5. LivaNova USA, Inc. $1,414 8 payments
  6. Sunovion Pharmaceuticals Inc. $375 31 payments
  7. AbbVie, Inc. $291 34 payments
  8. Novartis Pharmaceuticals Corporation $256 19 payments
  9. UCB, Inc. $227 7 payments
  10. Eisai Inc. $198 9 payments
  11. Other $760 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,975 6 payments
  2. Consulting Fee $5,375 6 payments
  3. Food and Beverage $4,060 193 payments
  4. Travel and Lodging $2,837 9 payments
  5. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. OXTELLAR XR $5,701 10 payments
  2. UBRELVY Neuroscience $5,174 19 payments
  3. Cenobamate $1,926 2 payments
  4. VNS Therapy $1,374 5 payments
  5. APTIOM $338 29 payments
  6. UBRELVY Neuroscience $234 27 payments
  7. Fycompa $198 9 payments
  8. Briviact $174 4 payments
  9. Soliris $148 5 payments
  10. XCOPRI $131 2 payments
  11. Other $1,220 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

2,778

Median for Neurology: 833

Drug cost

$354,336

Median for Neurology: $202,670

Branded share of claims

15.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fycompa Perampanel Brand 55 $70,640
Lacosamide Generic 321 $49,886
Briviact Brivaracetam Brand 22 $49,386
Nurtec Odt Rimegepant Sulfate Brand 25 $28,171
Levetiracetam Generic 507 $26,034
Aimovig Autoinjector Erenumab-Aooe Brand 26 $22,027
Emgality Pen Galcanezumab-Gnlm Brand 18 $16,320
Emgality Syringe Galcanezumab-Gnlm Brand 18 $13,028
Nayzilam Midazolam Brand 19 $12,335
Carbamazepine Er Carbamazepine Brand 57 $9,326

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$63,792

Medicare's payments for the services billed

Medicare patients

556

Average age 73

Services billed

1,016

304 women, 252 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 51%
Chronic kidney disease 45%
Ischemic heart disease 44%
Heart failure 38%
Alzheimer's or dementia 36%
Depression 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Briviact
  • UCB, Inc. $125
$125 22 —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record